ARMP

Over the past six months, Armata received an additional $3.7 million in non-dilutive funding from the U.S. Department of War for AP-SA02's Phase 3 development, bringing total DoW funding to approximately $32.4 million. The U.S. FDA granted Breakthrough Therapy designation to AP-SA02 for complicated Staphylococcus aureus bacteremia, expediting its review. The company participated in the H.C. Wainwright 28th Annual Global Investment Conference and announced a new publication on phage biology. Armata released its financial results for the second quarter of 2026 and provided a corporate update. H.C. Wainwright reiterated a 'Buy' rating and a $15.00 price target for ARMP following new data. The stock experienced a significant surge of over 475% due to strong Phase 2a data for AP-SA02 in complicated S. aureus bacteremia. Despite these positive developments, the stock declined by 49% over the past six months as of September 22, 2026, with a 52-week trading range between $2.94 and $16.34.